ArchiveMay 2014

Alemtuzumab approved in the UK…Let the European Experiment begin

A news report has been issued the National Institute for Health and Care Excellence (NICE) has issued final guidance recommending that Lemtrada should be reimbursed on the NHS, as an option for treating adults with active RRMS, within its marketing authorisation. So the “game” changes as more choice arises and a new first line appears. The FDA has expressed concerns about Alemtuzumab...

Modelling PPMS for Trials

Harding KE, Wardle M, Moore P, Tomassini V, Pickersgill T, Ben-Shlomo Y, Robertson NP. Modelling the natural history of primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014 May. pii: jnnp-2014-307791. doi: 10.1136/jnnp-2014-307791. [Epub ahead of print]BACKGROUND:A minority of patients with multiple sclerosis (MS) have primary progressive disease (PPMS). Treatment...

CCSVI May

It seems that when we post on this subject, it brings out the worse of some of the readers. So when your blood is boiling over some comment we have made and you have that urge to post something insulting, take a deep breath and stop. Epub: Napolitano et al. Endovascular treatment of chronic cerebro spinal venous insufficiency in patients with multiple sclerosis modifies circulating markers...

Who Chooses?

Here is a recent comment I picked off the web about treatment “Whether your Neuro will put you forward for it (a drug) is another question…….” This is a common theme.  Is it right that your Neuro plays God?… For many I suspect this is the view…and if they get it right you  will sing their praise.  Your Neuro has trained for years so that they...

Recovering from Optic Neuritis

Malik MT, Healy BC, Benson LA, Kivisakk P, Musallam A, Weiner HL, Chitnis T. Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis.Neurology. 2014 May. pii: 10.1212/WNL.0000000000000524. [Epub ahead of print] OBJECTIVE: To identify clinical and demographic features associated with the severity and recovery from acute optic neuritis (AON) episodes in...

Re Engineering Beta Interferon

Song K, Yoon IS, Kim NA, Kim DH, Lee J, Lee HJ, Lee S, Choi S, Choi MK, Kim HH, Jeong SH, Son WS, Kim DD, Shin YK. Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties. PLoS One. 2014;9(5):e96967. doi: 10.1371/journal.pone.0096967. eCollection 2014. The purpose of this study was to develop a biobetter version of recombinant human interferon-β 1a (rhIFN-β 1a)...

Simply monitoring brain function

Van Schependom J, D’hooghe MB, Cleynhens K, D’hooge M, Haelewyck MC, De Keyser J, Nagels G. The Symbol Digit Modalities Test as sentinel test for cognitive impairment in multiple sclerosis.Eur J Neurol. 2014 May. doi: 10.1111/ene.12463. [Epub ahead of print] BACKGROUND AND PURPOSE:Cognitive impairment (CI) is found in about half of the multiple sclerosis (MS) population and is an...

Red Hot Debates

Today is World MS Day Neuros love a good debate and contrary to what you may think there is not always a uniformity of ideas. They have been having debates for years and sometimes these occur in print.  Here is a list of examples that have occurred in the Multiple Sclerosis Journal over the past couple of years, with someone presenting the Yes over someone presenting the case for No. Epstein...

Are placebo controlled trials for RRMS ethical?

How about Are placebo-controlled trials for RRMS ethical? Surely an academic PI on a pharma trial or a pharma bod should be able to defend this position or maybe the people on the ethical review panels could make a case. Pharma hunts in packs and once one company gets a hit, others will follow.  First we had Gilenya (fingolimod) and then Siponimod (BAF312) for a different slice of the pie...

Translate

Categories

Recent Posts

Recent Comments

Archives